Regulatory and Compliance Updates news (page 2)

• 

  15 July 2026

  Repsol, Toyota, BMW and Bosch pilot cars on 100% renewable gasoline

  Six-month Spanish trial uses existing cars, 100% renewable gasoline and digital tracking to demonstrate drop-in fuel scalability without new vehicles or infrastructure.
• 

  15 July 2026

  Novo Nordisk wins EU authorisation for Wegovy pill and single‑dose 7.2 mg pen

  OASIS data showed ~17% mean weight loss and ~1 in 3 reached ≥20%; safety comparable to injectable semaglutide; wider roll‑out planned in H2 2026.
• 

  15 July 2026

  Johnson & Johnson Q2 2026 results and raises 2026 outlook

  Quarterly sales topped $25.3B; adjusted net earnings and EPS rose, free cash flow improved, and full-year revenue guidance was raised above $100B for the first time.
• 

  15 July 2026

  Roche: FDA grants Priority Review for Gazyva/Gazyvaro (obinutuzumab) in primary membranous nephropathy

  Priority Review follows MAJESTY phase III showing 36.9% complete remission at two years vs 5.7% with tacrolimus; FDA decision expected by Nov 2026.
• 

  14 July 2026

  Genentech’s Gazyva (obinutuzumab) granted FDA priority review for primary membranous nephropathy

  FDA granted priority review for obinutuzumab in pMN after Phase III MAJESTY showed markedly higher complete remission vs tacrolimus; FDA decision expected Nov 2026.
• 

  14 July 2026

  Olin and Huntsman: SEC Declares S‑4 Effective for Planned Merger

  SEC declared the Form S‑4 effective; special shareholder meetings set for Aug 25; closing expected H1 2027; transaction targets >$400M in synergies and broader vertical integration.

• 

  13 July 2026

  GSK’s Jemperli shows sustained clinical complete responses in dMMR/MSI‑H locally advanced rectal cancer

  Interim phase II results met primary endpoint (cCR12); trial suggests some patients may avoid chemo, radiation and surgery. Data to be shared with regulators including for US accelerated review.
• 

  13 July 2026

  Takeda and Indonesia to build national plasma ecosystem for PDMPs

  Fractionation license granted; $30M pilot to open plasma donation centers and assess local PDMP manufacturing, first donation center expected 2027.
• 

  11 July 2026

  Novo Nordisk: denecimig (Mim8) shows positive long-term Phase 3 FRONTIER4 results in haemophilia A

  Interim FRONTIER4 data show consistent safety and efficacy of denecimig across weekly, biweekly and monthly dosing, with low injection-site reactions and high zero-bleed rates.
• 

  10 July 2026

  Merck: FDA approves KEYTRUDA and KEYTRUDA QLEX with Padcev for perioperative MIBC

  FDA clears PD‑1 inhibitor plus antibody‑drug conjugate regimens with enfortumab vedotin as neoadjuvant and adjuvant therapy around cystectomy for adults with muscle‑invasive bladder cancer.
• 

  10 July 2026

  Hansoh Pharma: Ris‑Rez (risvutatug rezetecan) ARTEMIS‑008 shows overall survival benefit in Chinese SCLC patients

  Phase III trial met overall survival endpoint in advanced or relapsed small‑cell lung cancer in China, with consistent secondary benefits and no new safety signals.
• 

  10 July 2026

  European Commission adopts CRCF certification methodologies for carbon farming

  Technical rules set for certifying three carbon farming activities, enabling schemes to seek recognition under the CRCF framework and link land managers to finance.
• 

  10 July 2026

  POSCO HOLDINGS expands into lithium and energy under 'Triple-core' portfolio

  Triple-core portfolio to shore up supply chains; aims Global Top 5 lithium by 2033, KRW 16.7T investment in 2026–2028, and KRW 187T revenue by 2035.
• 

  9 July 2026

  INEOS and Recuro to build advanced pyrolysis recycling plant at Bamble (33,000 t/yr)

  Advanced pyrolysis plant at Bamble will process 33,000 t/yr of end-of-life plastics, powered by renewable energy to produce recycled ethylene and virgin-quality recycled polyethylene.
• 

  9 July 2026

  PwC study for Gasunie: CCS, low‑carbon hydrogen and hybrids are most cost‑effective for Dutch industry decarbonisation

  CCS, low‑carbon hydrogen and hybrid electrification are the cheapest routes to cut industrial CO2 — timely CO2/H2 infrastructure is essential.
• 

  9 July 2026

  Roche Elecsys IGRA TB gains CE mark for automated latent‑TB blood test

  Automated IGRA blood test delivers results in under 24 hours, with 19-minute per-patient processing and integration with high-throughput immunoassay systems to scale TB infection testing.
• 

  7 July 2026

  LYB and Mondelez launch Marabou wrappers with 75% recycled content

  Flexible food-grade film made from chemically recycled mixed plastic via ISCC PLUS mass-balance; MoReTec-1 to supply 50,000 t/yr feedstock; Taghleef and Amcor handled film and conversion.
• 

  6 July 2026

  Genmab: EC approves TEPKINLY (epcoritamab) + lenalidomide and rituximab for relapsed/refractory follicular lymphoma

  First bispecific‑based, chemotherapy‑free second‑line option in Europe after Phase 3 showed major PFS benefit and high complete response rates.
• 

  6 July 2026

  INEOS' Sir Jim Ratcliffe urges von der Leyen to protect Europe's chemical industry

  Warns China is dumping excess chemical capacity into Europe, calls for faster trade safeguards and ETS Investment Booster support for Project ONE (€5bn) low‑carbon ethylene.
• 

  3 July 2026

  EnviTec Biogas AG suspends 2025 dividend while shifting to biomethane

  AGM approves no dividend for 2025 to preserve financial flexibility; EEG support for ~16 MW and ~€100m investment plan to expand biomethane production by 2031.
• 

  2 July 2026

  XRG gains equity across all Rio Grande LNG trains

  Acquired an additional 7.6% in Trains 4–5, giving equity across all five construction trains; Trains 4–5 add ~12 MTPA and the project targets production in 1H 2027.
• 

  2 July 2026

  Commissioner Hoekstra pushes CCS scale-up across Europe

  EU aims for 50 Mtpa geological CO₂ storage by 2030; stakeholders call for investment in transport and storage, faster permitting, market demand and cross‑border cooperation.
• 

  2 July 2026

  Roche: Divarasib outperforms first‑generation KRAS G12C inhibitors in phase III Krascendo 1

  Head‑to‑head phase III in previously treated KRAS G12C NSCLC: divarasib improved progression‑free and overall survival versus sotorasib/adagrasib with a consistent safety profile.
• 

  1 July 2026

  Genentech's divarasib outperforms approved KRAS G12C inhibitors in Phase III NSCLC trial

  Head-to-head Phase III shows divarasib improves progression-free and overall survival versus sotorasib/adagrasib; safety consistent; data to be filed and presented.
• 

  1 July 2026

  Motherson and PureCycle produce Class-A bumper with 30% recycled polypropylene

  Class-A automotive bumper prototype uses 30% recycled polypropylene; technical details to be presented at Startup Autobahn Expo; aligns with upcoming EU ELV recycled-content mandates.
• 

  1 July 2026

  EU Commission opens antidumping probe into Chinese polyether polyols after PCC Rokita complaint

  Antidumping probe targets Chinese imports of polyether polyols; provisional tariffs possible within 7 months, final measures in up to 14 months.
• 

  1 July 2026

  Eni and Mercuria form equal global energy trading joint venture

  Independent holding with international trading hubs to manage commercialization and trading across oil, biofuels, gas, LNG and related logistics and infrastructure rights.
• 

  30 June 2026

  WuXi Biologics secures ANVISA GMP for MFG2, DP1 and DPPC to enable commercial anti‑PD‑L1 manufacturing

  ANVISA certified three Wuxi facilities with zero findings, allowing end‑to‑end commercial manufacture and supply of an anti‑PD‑L1 cancer immunotherapy and support for Latin America entry.
• 

  30 June 2026

  IHI-led seven-company low-carbon ammonia plan certified under Japan's price-gap scheme

  Low-carbon ammonia from India will be supplied to Japan for power, chemical and industrial use; certification enables price-gap support under the Hydrogen Society Promotion Act.
• 

  30 June 2026

  Roche’s Enspryng wins FDA Priority Review for at‑home subcutaneous TED treatment

  FDA accepted an sBLA and granted Priority Review for the first at‑home subcutaneous option for thyroid eye disease; decision expected 15 Oct 2026.